NOVOPROTEIN SCIENTIFIC INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.92 CNY | +1.76% |
|
+0.62% | -35.26% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 5,333 | 3,893 |
| Enterprise Value (EV) 1 | 3,515 | 2,481 |
| P/E ratio | 47.8 x | 308 x |
| Yield | 0.66% | 0.9% |
| Capitalization / Revenue | 20.2 x | 25.4 x |
| EV / Revenue | 13.3 x | 16.2 x |
| EV / EBITDA | 38.9 x | -63.4 x |
| EV / FCF | -5,48,47,525 x | -61,48,048 x |
| FCF Yield | -0% | -0% |
| Price to Book | 2.42 x | 1.78 x |
| Nbr of stocks (in thousands) | 70,175 | 70,175 |
| Reference price 2 | 76.00 | 55.48 |
| Announcement Date | 28/04/23 | 28/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 26 | 35.98 | 179.8 | 341.9 | 264.6 | 153.2 |
| EBITDA 1 | -12.39 | -8.421 | 97.71 | 180 | 90.46 | -39.16 |
| EBIT 1 | -13.57 | -9.716 | 96.04 | 176.2 | 81.98 | -49.22 |
| Operating Margin | -52.16% | -27% | 53.4% | 51.52% | 30.99% | -32.13% |
| Earnings before Tax (EBT) 1 | -13.53 | -9.708 | 94.15 | 176.2 | 106.2 | 6.222 |
| Net income 1 | -12.38 | -8.498 | 83.05 | 149 | 90.42 | 12.84 |
| Net margin | -47.62% | -23.62% | 46.18% | 43.58% | 34.18% | 8.38% |
| EPS | - | - | 5.229 | 3.730 | 1.590 | 0.1800 |
| Free Cash Flow | - | 1.91 | 52.18 | -40.13 | -64.09 | -403.6 |
| FCF margin | - | 5.31% | 29.01% | -11.74% | -24.23% | -263.45% |
| FCF Conversion (EBITDA) | - | - | 53.4% | - | - | - |
| FCF Conversion (Net income) | - | - | 62.83% | - | - | - |
| Dividend per Share | - | - | - | - | 0.5000 | 0.5000 |
| Announcement Date | 29/12/21 | 29/12/21 | 29/12/21 | 08/09/22 | 28/04/23 | 28/04/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1.43 | 0.33 | 93.8 | 102 | 1,818 | 1,412 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 1.91 | 52.2 | -40.1 | -64.1 | -404 |
| ROE (net income / shareholders' equity) | - | 248% | 174% | 64.4% | 7.07% | 0.59% |
| ROA (Net income/ Total Assets) | - | -20% | 58.9% | 32.1% | 3.59% | -1.33% |
| Assets 1 | - | 42.41 | 141.1 | 463.6 | 2,516 | -967 |
| Book Value Per Share | - | - | 6.490 | 6.840 | 31.30 | 31.20 |
| Cash Flow per Share | - | - | 4.320 | 3.600 | 13.30 | 12.30 |
| Capex 1 | 1.92 | 0.33 | 11.8 | 70 | 36.8 | 44.9 |
| Capex / Sales | 7.4% | 0.92% | 6.56% | 20.46% | 13.9% | 29.33% |
| Announcement Date | 29/12/21 | 29/12/21 | 29/12/21 | 08/09/22 | 28/04/23 | 28/04/24 |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -35.26% | 348M | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B |
- Stock Market
- Equities
- 688137 Stock
- Financials Novoprotein Scientific Inc.
